Iterum Therapeutics PLC (NASDAQ:ITRM) – Equities researchers at G.Research lowered their FY2019 earnings per share estimates for shares of Iterum Therapeutics in a research report issued on Thursday, August 15th. G.Research analyst K. Kedra now expects that the company will post earnings per share of ($7.10) for the year, down from their previous estimate of ($6.95). G.Research also issued estimates for Iterum Therapeutics’ FY2020 earnings at ($4.85) EPS, FY2021 earnings at ($3.70) EPS, FY2022 earnings at ($4.35) EPS and FY2023 earnings at ($1.70) EPS.
Iterum Therapeutics (NASDAQ:ITRM) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($1.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.50) by ($0.43). Iterum Therapeutics had a negative return on equity of 136.21% and a negative net margin of 11,956.64%.
Shares of NASDAQ:ITRM opened at $6.70 on Monday. Iterum Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $11.22. The business has a 50-day moving average of $6.65 and a two-hundred day moving average of $6.84. The stock has a market capitalization of $94.36 million, a P/E ratio of -0.94 and a beta of 2.05. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.10 and a quick ratio of 2.10.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Featured Story: Hold Rating
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.